Get the Stockscreener App
3.42
6.81%
-0.25
Pre-market:
3.48
0.06
+1.75%
Rocket Pharmaceuticals Inc stock is traded at $3.42, with a volume of 2.79M.
It is down -6.81% in the last 24 hours and up +7.55% over the past month.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
See More
Previous Close:
$3.67
Open:
$3.71
24h Volume:
2.79M
Relative Volume:
0.77
Market Cap:
$369.03M
Revenue:
-
Net Income/Loss:
$-258.08M
P/E Ratio:
-1.2436
EPS:
-2.75
Net Cash Flow:
$-202.32M
1W Performance:
+8.57%
1M Performance:
+7.55%
6M Performance:
-30.77%
1Y Performance:
-79.34%
1-Day Range:
$3.39
$3.73
1-Week Range:
$3.10
$3.74
52-Week Range:
$2.19
$18.89
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
3.42 | 396.01M | 0 | -258.08M | -202.32M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-25-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-30-25 | Downgrade | Evercore ISI | Outperform → In-line |
| May-28-25 | Downgrade | Goldman | Neutral → Sell |
| May-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-28-25 | Downgrade | Jefferies | Buy → Hold |
| May-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-28-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-27-25 | Downgrade | Needham | Buy → Hold |
| May-27-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Dec-30-24 | Initiated | Wedbush | Outperform |
| Dec-18-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-01-23 | Initiated | Morgan Stanley | Overweight |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Nov-01-22 | Initiated | BTIG Research | Buy |
| Jul-08-22 | Initiated | Raymond James | Outperform |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Feb-18-21 | Initiated | Needham | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-02-20 | Initiated | JP Morgan | Overweight |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-26-19 | Initiated | Piper Jaffray | Overweight |
| Apr-23-19 | Initiated | Robert W. Baird | Outperform |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Feb-05-19 | Initiated | Oppenheimer | Outperform |
| Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
| Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
Will Rocket Pharmaceuticals Inc. Equity Warrant stock benefit from upcoming earnings reportsJuly 2025 Highlights & Community Supported Trade Ideas - newser.com
Bronstein, Gewirtz & Grossman, LLC Encourages Rocket Pharmaceuticals, Inc. (RCKT) Investors to Inquire about Securities Investigation - ACCESS Newswire
Is Rocket Pharmaceuticals Inc. Equity Warrant stock bottoming outQuarterly Risk Review & Free Real-Time Market Sentiment Alerts - newser.com
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Will Rocket Pharmaceuticals Inc. stock go up soonJuly 2025 Movers & Comprehensive Market Scan Insights - newser.com
Should you hold or exit Rocket Pharmaceuticals Inc. now2025 Trading Volume Trends & Real-Time Buy Signal Notifications - newser.com
Published on: 2025-10-10 06:17:17 - newser.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Receives "Sell (E+)" Rating from Weiss Ratings - MarketBeat
Published on: 2025-10-10 04:39:16 - newser.com
Building trade automation scripts for Rocket Pharmaceuticals Inc. Equity Warrant2025 Macro Impact & Step-by-Step Trade Execution Guides - newser.com
How to use Fibonacci retracement on Rocket Pharmaceuticals Inc. Equity WarrantMarket Volume Report & High Win Rate Trade Alerts - newser.com
How sentiment analysis helps forecast Rocket Pharmaceuticals Inc. Equity WarrantPortfolio Update Report & Weekly High Potential Stock Alerts - newser.com
Will Rocket Pharmaceuticals Inc. (9IP1) stock profit from fiscal stimulusEarnings Beat & Intraday High Probability Alerts - newser.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Investors to Reach Out - ACCESS Newswire
How to manage a losing position in Rocket Pharmaceuticals Inc. Equity Warrant2025 AllTime Highs & Free Technical Confirmation Trade Alerts - newser.com
Published on: 2025-10-09 05:44:17 - newser.com
Published on: 2025-10-09 03:18:17 - newser.com
Can a trend reversal in Rocket Pharmaceuticals Inc. Equity Warrant lead to recovery2025 Breakouts & Breakdowns & Risk Managed Investment Strategies - newser.com
Automated trading signals detected on Rocket Pharmaceuticals Inc. Equity WarrantWeekly Market Report & Safe Entry Point Identification - newser.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Pass Below 50-Day Moving AverageWhat's Next? - MarketBeat
What drives Rocket Pharmaceuticals Inc stock priceBollinger Bands Signals & Free Dynamic Capital Growth - earlytimes.in
Rocket Pharmaceuticals Pulls BLA for Fanconi Anemia Gene Therapy RP-L102 - CGTLive®
How Rocket Pharmaceuticals Inc. Equity Warrant stock reacts to global recession fearsJuly 2025 Trends & Risk Controlled Daily Trade Plans - newser.com
Is Rocket Pharmaceuticals Inc. Equity Warrant stock ready for a breakout2025 Trading Recap & Verified Swing Trading Watchlists - newser.com
Rocket Pharmaceuticals Inc. Equity Warrant stock volume spike explainedPortfolio Growth Summary & High Accuracy Swing Entry Alerts - newser.com
Using AI based signals to follow Rocket Pharmaceuticals Inc. Equity WarrantMarket Performance Summary & Weekly High Conviction Ideas - newser.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Stockholders to Reach Out - ACCESS Newswire
Combining price and volume data for Rocket Pharmaceuticals Inc. Equity WarrantEarnings Risk Report & AI Powered Trade Plan Recommendations - newser.com
Real time social sentiment graph for Rocket Pharmaceuticals Inc. Equity WarrantTrade Signal Summary & Daily Chart Pattern Signal Reports - newser.com
Is Rocket Pharmaceuticals Inc. Equity Warrant stock positioned well for digital economyGap Up & Community Verified Trade Signals - newser.com
Understanding Rocket Pharmaceuticals Inc. Equity Warrant’s price movementJuly 2025 PreEarnings & Accurate Intraday Trade Tips - newser.com
Is now a turning point for Rocket Pharmaceuticals Inc.2025 Historical Comparison & AI Powered Buy and Sell Recommendations - newser.com
Published on: 2025-10-05 06:51:42 - newser.com
Is Rocket Pharmaceuticals Inc. Equity Warrant stock resilient to inflationMarket Activity Report & Real-Time Volume Spike Alerts - newser.com
Is Rocket Pharmaceuticals Inc. (9IP1) stock a buy for dividend portfolios2025 Retail Activity & Safe Entry Zone Identification - newser.com
Comparing Rocket Pharmaceuticals Inc. Equity Warrant in custom built stock radarsJuly 2025 WrapUp & Weekly Sector Rotation Insights - newser.com
Rocket Pharmaceuticals board member Pedro Granadillo resigns - StreetInsider
Leerink Partners Maintains Rocket Pharmaceuticals (RCKT) Market Perform Recommendation - Nasdaq
Rocket Pharmaceuticals announces board resignation of Pedro Granadillo - Investing.com
Rocket Pharmaceuticals Pulls FDA Filing for Rare Blood Disorder Gene Therapy - MedCity News
Rocket Pharmaceuticals (RCKT) Withdraws U.S. Filing for Gene The - GuruFocus
Leerink Partners Adjusts Rocket Pharmaceuticals Price Target to $7 From $9, Maintains Market Perform Rating - MarketScreener
Rocket Pharma pulls BLA for gene therapy RP-L102 in the USA - The Pharma Letter
Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy - Stocktwits
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Cut to $7.00 by Analysts at Leerink Partners - MarketBeat
RCKT: Analyst Lowers Price Target for Rocket Pharmaceuticals | R - GuruFocus
Leerink Partners Maintains Rocket Pharmaceuticals(RCKT.US) With Hold Rating, Announces Target Price $7 - 富途牛牛
Rocket Pharmaceuticals (RCKT) Halts U.S. Application for Gene Th - GuruFocus
Using R and stats models for Rocket Pharmaceuticals Inc. Equity Warrant forecasting2025 Market Outlook & Low Risk Profit Maximizing Plans - newser.com
Rocket Pharmaceuticals withdraws US application for blood disorder gene therapy - MarketScreener
Rocket Pharmaceuticals withdraws BLA for gene therapy RP-L102 in the US - Investing.com
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rocket Pharmaceuticals Inc Stock (RCKT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Militello John | See Remarks |
Aug 18 '25 |
Sale |
3.06 |
699 |
2,142 |
56,285 |
| Militello John | See Remarks |
Aug 19 '25 |
Sale |
3.00 |
361 |
1,082 |
55,924 |
| Schwartz Jonathan David | See Remarks |
Aug 18 '25 |
Sale |
3.06 |
1,680 |
5,149 |
222,414 |
| Schwartz Jonathan David | See Remarks |
Aug 19 '25 |
Sale |
3.00 |
805 |
2,412 |
221,609 |
| Wilson Martin | General Counsel |
Aug 18 '25 |
Sale |
3.06 |
1,004 |
3,077 |
136,050 |
| Wilson Martin | General Counsel |
Aug 19 '25 |
Sale |
3.00 |
588 |
1,762 |
135,462 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):